protein

CLUSTERIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CLUSTERIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

298Connections

3Hypotheses

0Analyses

50Outgoing

50Incoming

5Experiments

0Debates

Summary

CLUSTERIN is a protein involved in neurodegeneration research. Key relationships include: associated with, regulates, activates. Associated with ALS, Aging, Als. Connected to 115 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	CLU
Full Name	Clusterin
Aliases	Page for CLU Gene
Chromosome	8p21.1.
Protein Family	Apolipoprotein / extracellular chaperone
Function	It binds to non-native, misfolded, or aggregation-prone proteins and maintains them in a soluble state suitable for subsequent processing (Wyatt et al., 2009)
Primary Expression	Secreted (sCLU), cytoplasmic/nuclear (nCLU/iCLU)
Molecular Weight	80 kDa
Amino Acids	522 aa
Exons	9
Pathways	Apoptosis, Complement, Immune Response, Mitophagy
UniProt ID	P10909
NCBI Gene ID	1115
Ensembl ID	ENSG00000120885
OMIM	185551
GeneCards	CLU
Human Protein Atlas	CLU
Associated Diseases	aging, Als, Alzheimer, Alzheimer Disease
Interactions	AKT, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID, Amyloid Beta, AND
KG Connections	292 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: CLUSTERIN — AlphaFold P10909 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Clusterin (CLU / Apolipoprotein J)

protein · 1287 words

→

Pathway Diagram

graph TD
    CLUSTERIN["CLUSTERIN"]
    Cancer{"Cancer"}
    CLUSTERIN -->|"regulates"| Cancer
    Neurodegeneration{"Neurodegeneration"}
    CLUSTERIN -->|"associated with"| Neurodegeneration
    Alzheimer{"Alzheimer"}
    CLUSTERIN -->|"associated with"| Alzheimer
    CLUSTERIN -->|"activates"| Alzheimer
    Als{"Als"}
    CLUSTERIN -->|"activates"| Als
    CLUSTERIN -->|"activates"| Cancer
    CLUSTERIN -->|"expressed in"| Alzheimer
    Tumor{"Tumor"}
    CLUSTERIN -->|"expressed in"| Tumor
    Senescence{"Senescence"}
    CLUSTERIN -->|"expressed in"| Senescence
    ALS{"ALS"}
    CLUSTERIN -->|"causes"| ALS
    Parkinson{"Parkinson"}
    CLUSTERIN -->|"causes"| Parkinson
    LC3["LC3"]
    CLUSTERIN -->|"activates"| LC3
    CLU["CLU"]
    CLU -->|"regulates"| CLUSTERIN
    PPARGC1A["PPARGC1A"]
    PPARGC1A -->|"regulates"| CLUSTERIN
    BAX["BAX"]
    BAX -->|"activates"| CLUSTERIN
    C1S["C1S"]
    C1S -->|"regulates"| CLUSTERIN
    PPARG["PPARG"]
    PPARG -->|"regulates"| CLUSTERIN
    CLU -->|"activates"| CLUSTERIN
    CLU -->|"therapeutic target"| CLUSTERIN
    BAX -->|"regulates"| CLUSTERIN
    C1Q["C1Q"]
    C1Q -->|"activates"| CLUSTERIN
    RS6656401["RS6656401"]
    RS6656401 -->|"associated with"| CLUSTERIN
    RS3919533["RS3919533"]
    RS3919533 -->|"associated with"| CLUSTERIN
    BIN1["BIN1"]
    BIN1 -->|"activates"| CLUSTERIN
    style CLUSTERIN fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (203)

Target	Relation	Type	Str
ds-83b31ef18d49	provides_data_for	dataset	1.00
Alzheimer's disease pathology	involved_in	mechanism	0.85
Immune dysregulation	involved_in	process	0.80
Plasma complement protein levels	biomarker_for	biomarker	0.80
Als	activates	disease	0.75
Alzheimer	associated_with	disease	0.75
Apoptosis	activates	pathway	0.70
Parkinson's Disease	biomarker_for	disease	0.70
ALZHEIMER	associated_with	gene	0.70
Dementia	associated_with	disease	0.65
Als	therapeutic_target	disease	0.65
Als	regulates	disease	0.65
Parkinson	activates	disease	0.65
Parkinson	therapeutic_target	disease	0.65
Parkinson's Disease	associated_with	disease	0.65
Als	associated_with	disease	0.65
Dementia	regulates	disease	0.65
Aging	associated_with	disease	0.65
Als	expressed_in	disease	0.65
Ms	therapeutic_target	disease	0.65
Alzheimer	contributes_to	disease	0.65
ALS	activates	disease	0.65
Multiple Sclerosis	activates	disease	0.65
Aging	contributes_to	disease	0.65
Inflammation	regulates	disease	0.65
Alzheimer	expressed_in	disease	0.65
Tumor	expressed_in	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Inflammation	contributes_to	disease	0.65
ALS	expressed_in	disease	0.65
Cancer	regulates	disease	0.65
ALS	causes	disease	0.65
Parkinson	causes	disease	0.65
Senescence	expressed_in	disease	0.65
Alzheimer	interacts_with	disease	0.65
ALS	interacts_with	disease	0.65
Alzheimer	activates	disease	0.65
Cancer	activates	disease	0.65
TGM2	expressed_in	gene	0.60
CX3CR1	expressed_in	gene	0.60
CLU	inhibits	gene	0.60
CLU	expressed_in	gene	0.60
SORL1	activates	gene	0.60
CLU	activates	gene	0.60
Insulin Receptor	activates	protein	0.60
Rb	regulates	protein	0.60
Mitophagy	regulates	pathway	0.60
Complement	regulates	pathway	0.60
GENES	activates	gene	0.60
Autophagy	expressed_in	pathway	0.60

Incoming (95)

Source	Relation	Type	Str
ds-83b31ef18d49	data_in	dataset	1.00
BACE1	regulates_expression	gene	0.90
OPTN	regulates	gene	0.80
CLU	regulates	gene	0.70
CLU	encodes	gene	0.70
APOPTOSIS	activates	gene	0.70
ASTROCYTES	activates	gene	0.60
NEURODEGENERATION	associated_with	gene	0.60
COMPLEMENT	regulates	gene	0.60
ALZHEIMER	contributes_to	gene	0.60
ALZHEIMER	expressed_in	gene	0.60
NEURON	activates	gene	0.60
APOE	activates	gene	0.60
TAU	activates	gene	0.60
SORL1	activates	gene	0.60
AKT	activates	gene	0.60
PI3K	activates	gene	0.60
APP	interacts_with	gene	0.60
REELIN	interacts_with	gene	0.60
NEURODEGENERATIVE DISEASES	expressed_in	gene	0.60
ALZHEIMER'S DISEASE	expressed_in	gene	0.60
AUTOPHAGY	expressed_in	gene	0.60
OXIDATIVE STRESS	expressed_in	gene	0.60
ROS	activates	gene	0.60
MITOPHAGY	regulates	gene	0.60
MITOCHONDRIA	regulates	gene	0.60
CANCER	regulates	gene	0.60
ALZHEIMER'S DISEASE	associated_with	gene	0.60
RS6656401	implicated_in	gene	0.60
RS3919533	implicated_in	gene	0.60
CLU	activates	gene	0.60
CLU	therapeutic_target	gene	0.60
BAX	regulates	gene	0.60
C1Q	activates	gene	0.60
BIN1	activates	gene	0.60
CDKN2A	expressed_in	gene	0.60
PRKCB	expressed_in	gene	0.60
BECN1	expressed_in	gene	0.60
LC3	activates	gene	0.60
TREM2	associated_with	gene	0.60
CLU	associated_with	gene	0.60
SORL1	associated_with	gene	0.60
BDNF	associated_with	gene	0.60
APP	associated_with	gene	0.60
CR1	associated_with	gene	0.60
CLU	expressed_in	gene	0.60
CFH	implicated_in	gene	0.60
CR1	regulates	gene	0.60
BACE1	regulates	protein	0.60
CX3CR1	expressed_in	gene	0.60

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Magnetosonic-Triggered Transferrin Receptor Clustering	0.719	neurodegeneration	Blood-brain barrier transport mechanisms
Clusterin (APOJ) Secretion Deficit	0.660	neurodegeneration	Which specific factors in conditioned me
CSF ApoE- and clusterin-rich lipoprotein particles stabilize	0.606	neurodegeneration	Which specific CSF molecular components

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
iPSC-derived endothelial cell iron uptake with RLS CSF exposure	exploratory	restless legs syndrome	0.900	0.00	iPSC-derived human endothelial	proposed	N/A
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - Compare uptake with/without magnetic particles using tight junc	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$120,000
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. [PMID:40425446]	Sehlin D, Hultqvist G, Michno W, Aguilar	J Prev Alzheimers Dis	2025	1
Effect of ferroptosis on chronic cerebral hypoperfusion in vascular dementia. [PMID:37709116]	Fu P, Chen Y, Wu M, Bao B, Yin X, Chen Z	Exp Neurol	2023	1
On Iron Metabolism and Its Regulation. [PMID:33925597]	Vogt AS, Arsiwala T, Mohsen M, Vogel M,	Int J Mol Sci	2021	1
Transferrin Receptor Is a Specific Ferroptosis Marker. [PMID:32160546]	Feng H, Schorpp K, Jin J, Yozwiak CE, Ho	Cell Rep	2020	1
Transferrin and transferrin receptors update. [PMID:29969719]	Kawabata H	Free Radic Biol Med	2019	1
Time- and dose-dependent effects of bacterial infection on iron metabolism, infl [PMID:41619877]	Lu Y, Zhang Y, Niu C	Comp Biochem Physiol A Mol Int	2026	0
Ayanin combats against barium sulphate nanoparticles induced hepatotoxicity via [PMID:41666660]	Zhu D, Lu Y, Jamil S, Ashfaq H, Al-Emam	J Trace Elem Med Biol	2026	0
Role of iron and TfR1 in the application of high‑dose ascorbate against pancreat [PMID:41789665]	Piotrowsky A, Leischner C, Schmieder H,	Oncol Rep	2026	0
Yangxin granules exert cardioprotective effects against acute myocardial infarct [PMID:41868900]	Huo G, Zhou Y, Wu Z, Sun S, Zhu G, Cheng	American journal of translatio	2026	0
Conformational dynamics study of TfR1 upon transferrin binding via NMA and MD si [PMID:41921418]	Zemmouche M, Falque G, Cadet F, Gardebie	Journal of molecular graphics	2026	0
[Effects of acupuncture on ferroptosis and ferritinophagy in cerebral ischemia-r [PMID:41839581]	Wang YF, Dong YS	Zhen ci yan jiu = Acupuncture	2026	0
The therapeutic potential of Piezo1 channel-mediated ferroptosis and its inhibit [PMID:41854751]	Nan K, Zhang L, Zhao Y, Yin S, Peng Y, H	Apoptosis : an international j	2026	0
The Role of Artemisinin and its Derivatives in Cancer Therapy via Ferroptosis: A [PMID:41833023]	Osmanlioglu Dag SR, Tatli Cankaya II, Oz	Anti-cancer agents in medicina	2026	0
Raccoon eyes [PMID:35789012]	Ning Junjie	Journal of Paediatrics and Chi	2023	0
The Trend of Immunotherapy Combined with Nanomedicine. [PMID:34789123]	Shigao Huang; Qi Zhao	Current medicinal chemistry	2022	0
Test-retest reliability for performance-based outcome measures among individuals [PMID:35123456]	["Sions J", "Donohoe M", "Beisheim-Ryan	BMC musculoskeletal disorders	2022	0
Interfacial Imide Polymerization of Functionalized Filled Microcapsule Templates [PMID:36234567]	["Wei Z", "Ma X", "Wang P", "Pan J"]	Nanomaterials (Basel, Switzerl	2022	0
The impact of COVID-19 and non-pharmaceutical interventions on energy returns wo [PMID:36567890]	["Saif-Alyousfi A", "Saha A"]	Sustainable cities and society	2021	0
Implications of relationships with family, friends, and neighbors for changes in [PMID:33245678]	["Fuller H"]	Journal of women & aging	2021	0
[Longitudinal Direct Closure of Mitral Anterior Leaflet Large Perforation for In [PMID:34876543]	Morizumi S, Enomoto Y, Ikeda K, Suzuki Y	Kyobu geka. The Japanese journ	2021	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity